1 not yet recruiting, 1 unknown. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 1, Unknown 1 |
Follow HER2 Expression: new trials by email Literature Review of HER2 Expression trials Research Report on HER2 Expression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor Trastuzumab Rezetecan - Solid Tumors, Neoplasms (Cancer / Tumors) | Phase 2 | Not yet recruiting | Haihua Yuan | 15 | 2026-06-15 | 2026-06-08 |
| RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC Disitamab Vedotin and Toripalimab - Muscle Invasive Bladder Cancer, HER2 Expression | Phase 2 | Unknown | RenJi Hospital | 6 | 2023-08-01 | 2023-08-31 |
Biliary Tract Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Head and Neck Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Stomach Neoplasms (1) · Uterine Cervical Neoplasms (1)
Biliary Tract Diseases (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Genital Diseases (1) · Genital Diseases, Female (1)
RC48 antibody (1) · disitamab vedotin (1) · toripalimab (1)
Haihua Yuan (1) · RenJi Hospital (1)
China (1)
Haige Chen (1)